Fortress Biotech to Present Corporate Overview at ROTH MKM 2023 Healthcare Opportunities Conference
Fortress Biotech, a leading biopharmaceutical company, is set to present a corporate overview at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City. The event will take place on Thursday, October 12, 2023, at 11:00 a.m. ET. Dr. Lindsay A. Rosenwald, Chairman, President, and CEO of Fortress Biotech, will provide insights into the company’s innovative approach to acquiring, developing, and commercializing therapeutic products.
Fortress Biotech is known for its efficient strategies in acquiring and monetizing promising therapeutic products and product candidates. With a diverse portfolio of eight marketed prescription pharmaceutical products and over 25 programs in development, Fortress is actively creating value for its shareholders. The company’s focus areas include oncology, rare diseases, and gene therapy, enabling it to address significant market needs.
Through strategic partnerships with renowned academic research institutions and biopharmaceutical companies such as AstraZeneca, City of Hope, and St. Jude Children’s Research Hospital, Fortress Biotech maximizes the potential of each opportunity. By leveraging its extensive industry expertise and network, the company continues to expand its pipeline of product opportunities.
The ROTH MKM 2023 Healthcare Opportunities Conference provides an ideal platform for Fortress Biotech to showcase its achievements and future prospects. Investors, industry experts, and healthcare professionals will have the opportunity to gain valuable insights into the company’s streamlined operating structure and its commitment to efficient drug development.
For more information about Fortress Biotech and its innovative biopharmaceutical solutions, visit www.fortressbiotech.com.
Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
Phone: (781) 652-4500
Email: ir@fortressbiotech.com
Media Relations:
Tony Plohoros
6 Degrees
Phone: (908) 591-2839
Email: tplohoros@6degreespr.com